JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Mirati Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

0

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

Max

Schlüsselkennzahlen

By Trading Economics

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-0.05% downside

Nachrichtenstimmung

By Acuity

97%

3%

351 / 371 Ranking in Healthcare

Mirati Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Okt. 2025, 18:41 UTC

Ergebnisse

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. Okt. 2025, 18:31 UTC

Ergebnisse

Correction to Procter & Gamble to Focus on Innovation

24. Okt. 2025, 16:25 UTC

Wichtige Markttreiber

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. Okt. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Okt. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. Okt. 2025, 21:07 UTC

Ergebnisse

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. Okt. 2025, 20:58 UTC

Ergebnisse

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 20:40 UTC

Ergebnisse

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. Okt. 2025, 20:24 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:23 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:13 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. Okt. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. Okt. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. Okt. 2025, 19:33 UTC

Ergebnisse

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. Okt. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. Okt. 2025, 18:52 UTC

Ergebnisse

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:41 UTC

Ergebnisse

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:03 UTC

Ergebnisse

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. Okt. 2025, 18:02 UTC

Ergebnisse

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. Okt. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. Okt. 2025, 16:57 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. Okt. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. Okt. 2025, 16:44 UTC

Market Talk
Ergebnisse

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. Okt. 2025, 16:39 UTC

Market Talk
Ergebnisse

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. Okt. 2025, 16:33 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:23 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 16:07 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer-Vergleich

Kursveränderung

Mirati Therapeutics Inc Prognose

Kursziel

By TipRanks

-0.05% Nachteil

12-Monats-Prognose

Durchschnitt 58.67 USD  -0.05%

Hoch 59 USD

Tief 58 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Mirati Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

0

Buy

5

Halten

0

Sell

Stimmung

By Acuity

351 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

$

Über Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
help-icon Live chat